Filing Flows › Ensysce Biosciences (ENSC) › Q2 2026 › vs Q2 2025
Ensysce Biosciences (ENSC) Q2 2026 vs Q2 2025 (year over year)
Ensysce Biosciences's revenue fell $207K (-15%) from $1.4M in Q2 2025 to $1.2M in Q2 2026.
Ensysce Biosciences, Q2 2026: revenue $1.2M (-15% year over year), operating margin -221.3%, net loss $2.6M, operating cash flow −$2.0M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.2M | $1.4M | −$207K | -15% |
| Other income, net | $6K | $17K | −$11K | -68% |
| Net loss | $2.6M | $1.7M | $837K | +48% |
| Costs & expenses | $3.7M | $3.1M | $619K | +20% |
| Operating costs | $3.7M | $3.1M | $619K | +20% |
| Research & development | $2.5M | $1.9M | $548K | +29% |
| General & admin | $1.3M | $1.2M | $70K | +6% |
| Operating cash sources | $2.6M | $1.7M | $837K | +48% |
| Depreciation | $7K | $0 | $7K | — |
| Share-based compensation | $2K | $187K | −$185K | -99% |
| Working capital & other | $600K | −$1.2M | $1.8M | — |
| Cash used in operations | $2.0M | $2.7M | −$744K | -28% |
| Net loss absorbed | $2.6M | $1.7M | $837K | +48% |
Questions
How much did Ensysce Biosciences's revenue grow year over year in Q2 2026?
Ensysce Biosciences's revenue fell $207K (-15%) from $1.4M in Q2 2025 to $1.2M in Q2 2026.